
Briefing · From the Watchtower
Belzutifan plus lenvatinib wins positive EU CHMP opinion in kidney cancer
Merck's HIF-2alpha inhibitor combination clears Europe's scientific committee for ccRCC after PD-(L)1 therapy, on LITESPARK-011 progression-free survival data.
What happened
The EU's Committee for Medicinal Products for Human Use issued a positive opinion on 13 November 2026 recommending belzutifan (Welireg) in combination with lenvatinib for adults with advanced renal cell carcinoma with a clear cell component who have had prior anti-PD-1 or anti-PD-L1 therapy [1]. The opinion rests on progression-free survival results from the Phase 3 LITESPARK-011 trial [1].
A CHMP positive opinion is a recommendation, not an authorisation. The European Commission issues the binding marketing decision. On the standard EMA procedure the Commission usually acts within about two months of the opinion, which would place a decision around the second half of January 2027; treat that as Prognyx's estimate from the standard clock, not a published target date.
Why it matters
The US approval came earlier. FDA approved the same belzutifan-lenvatinib combination for advanced ccRCC after PD-1/PD-L1 therapy on 24 September 2026, on LITESPARK-011 (NCT04586231), an open-label randomized trial of 747 patients that compared the combination against cabozantinib in patients who progressed on or after a checkpoint inhibitor [2]. A European recommendation extends that post-immunotherapy franchise into the EU and, per Merck, would be the first approved pairing of a HIF-2alpha inhibitor with a multi-targeted VEGFR-TKI in the region if the Commission concurs [1]. Belzutifan is already approved as monotherapy for von Hippel-Lindau disease-associated tumors including RCC [6]; the lenvatinib combination is the franchise's move into advanced sporadic ccRCC after immunotherapy.
Who is exposed
This matters most for companies building HIF-2alpha programs around belzutifan rather than against it. Arcus Biosciences will initiate a randomized ARC-20 cohort in the fourth quarter of 2026 testing its HIF-2alpha inhibitor casdatifan plus tivozanib versus tivozanib alone in patients who received two or more prior lines, explicitly including a belzutifan-containing regimen [5]. That design treats belzutifan as an established prior line to differentiate against, and a second major-market endorsement hardens that assumption.
Merck is also working on its own next step for the backbone.
Track belzutifan (WELIREG) plus lenvatinib
The next move on belzutifan (WELIREG) plus lenvatinib (readout, FDA/EMA action, deal) by email, the day we publish it.
One email per briefing. Double opt-in, no open tracking. Privacy.
Compare active trials live → · Request a brief on your target →
What to watch next
- The European Commission's binding decision: Prognyx estimates the second half of January 2027 on the standard EMA clock, which the dossier does not confirm.
- The quantitative LITESPARK-011 results (hazard ratio, median PFS): not present in public records in this dossier.
- Arcus Biosciences' ARC-20 casdatifan plus tivozanib cohort initiation, planned for the fourth quarter of 2026 [5].
- LITESPARK-034 primary completion, 27 November 2030 [3].
The now-what
Three moves for a ccRCC developer. First, update comparator assumptions: belzutifan plus lenvatinib is approved in the US and recommended in the EU for post-checkpoint ccRCC, so trial designs and payer dossiers in that line should treat it as an available standard-of-care comparator or prior line. Second, for HIF-2alpha challengers, the Arcus route of positioning behind belzutifan is now backed by a second regulator's committee; differentiation has to come from the post-belzutifan population or tolerability, not from being early to the HIF-2alpha clinic. Third, on BD timing, the Commission decision window in early 2027 is the next EU inflection for partnering around later-line ccRCC assets.
What Prognyx could not verify
Prognyx read the CHMP opinion from Merck's own release and could not locate an EMA primary record in this dossier. The quantitative LITESPARK-011 outcomes are not in the public records provided, the European Commission's decision date is not confirmed, and the "first and only" HIF-2alpha plus VEGFR-TKI claim is Merck's framing, not independently checked.
Verdict: moderate threat for later-line ccRCC challengers; the window to adjust EU comparator and positioning strategy runs through the expected Commission decision in early 2027.
The Watchtower, by email
The next move on belzutifan (WELIREG) plus lenvatinib, the day it happens.
You have just read a briefing on belzutifan (WELIREG) plus lenvatinib. The next readout, FDA/EMA action or deal reaches you by email the day we publish it. One email per briefing, nothing else.
Double opt-in. Never sold, no open tracking. Privacy.
Questions this briefing answers
Does the CHMP opinion mean belzutifan plus lenvatinib is approved in the EU?
No. A CHMP positive opinion is a recommendation to the European Commission, which issues the binding marketing authorisation. The dossier does not carry a confirmed Commission decision date.
Which trial supports the recommendation?
The Phase 3 LITESPARK-011 trial (NCT04586231), on its progression-free survival results. The same trial, an open-label randomized study of 747 patients comparing belzutifan plus lenvatinib against cabozantinib after checkpoint-inhibitor progression, supported the US FDA approval on 24 September 2026.
Sources: every claim traces to the primary record
- Merck & Co newsroom: positive EU CHMP opinion for Welireg (belzutifan) with lenvatinib
- FDA: approval of belzutifan with lenvatinib for advanced RCC with a clear cell component
- ClinicalTrials.gov NCT07489495 (LITESPARK-034)
- SEC 8-K (Exelixis): LITESPARK-034 initiation, April 2026
- SEC 8-K (Arcus Biosciences): casdatifan ARC-20 cohort
- DailyMed (FDA label): Welireg (belzutifan)
How this briefing was produced: Drafted and audited by the Prognyx engine against the primary sources cited above, then published automatically for clearing the audit threshold set by Rali Filali. Below that threshold, a briefing is not published. The full method.
Get a free sample competitive brief on one of your assets, sourced, sharp, no strings.
Request a sample brief → Or read how Prognyx runs continuous oncology competitive intelligence.
Prognyx briefings are built from public information and reflect Prognyx's analysis. They are not investment advice and do not promote any product or off-label use.